Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 7/20 | 0.53 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30939897 | 1.00 | HASPIN (0.53) | HASPINDYRK2KITPDGFRAFGFR3 | |
| SCHEMBL16123595 | 0.86 | HASPIN (0.73) | HASPINDYRK2DYRK1AHTR2AHTR2C | |
| SCHEMBL30939902 | 0.85 | DYRK1A (0.55) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL30939925 | 0.85 | HASPIN (0.52) | HASPINDYRK2DYRK1AHTR2AHTR2C | |
| SCHEMBL16123596 | 0.85 | DYRK1A (0.55) | HASPINDYRK1AHTR2AHTR2C | |
| SCHEMBL16097994 | 0.85 | HASPIN (0.52) | HASPINDYRK2DYRK1AHTR2AHTR2C | |
| SCHEMBL16126043 | 0.83 | HASPIN (0.48) | HASPINDYRK2KITPDGFRAFGFR3 | |
| SCHEMBL15227864 | 0.83 | HASPIN (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL30939871 | 0.83 | HASPIN (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL16123508 | 0.81 | HASPIN (0.48) | HASPINDYRK2DYRK1AHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3915987-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2023-12-13 | — | — | EP | disclosed |
| EP-3915987-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2023-12-13 | — | — | EP | disclosed |
| US-11267814-B2 | Compounds for bone growth | OsteoQC, Inc. | 2022-03-08 | — | — | US | disclosed |
| EP-3915987-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteoqc Inc. (CA) | 2021-12-01 | — | — | EP | disclosed |
| EP-3915987-A1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | Osteoqc Inc. (CA) | 2021-12-01 | — | — | EP | disclosed |
| CN-113416187-A | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-105120863-B | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-2968284-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2021-04-21 | — | — | EP | disclosed |
| EP-2968284-B1 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOQC INC (CA) | 2021-04-21 | — | — | EP | disclosed |
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2020-06-04 | — | — | US | disclosed |
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2020-06-04 | — | — | US | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | OSSIFI THERAPEUTICS LLC | 2017-10-19 | — | — | US | disclosed |
| WO-2014153203-A2 | ALKYL-AMINE HARMINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSSIFI INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172538-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | HASPIN 1246/4885DYRK2 4607/4885KIT 667/4885 |
| US-20170298059-A1 | COMPOUNDS FOR BONE GROWTH | FGF1, FGF2, BMP2 | HASPIN 1246/4885DYRK2 4607/4885KIT 667/4885 |
| US-11267814-B2 | Compounds for bone growth | FGF1, FGF2, BMP2 | HASPIN 1246/4885DYRK2 4607/4885KIT 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.